Skip to content

Clinton Foundation announces new price cuts for tenofovir and second-line drugs

Substantial HIV reduction persists for 2-3 weeks with single dose of PRO-140 antibody

Tenofovir and Truvada licensed in South Africa

Maraviroc recommended for accelerated approval in the US

Abbott offers Aluvia to Thailand in return for compulsory licensing halt

Discovery of an HIV inhibitor in human blood points to new type of fusion inhibitor

Chinese company to develop CCR5 inhibitor with Avexa

Abbott announces Kaletra price cut for lower middle-income countries, makes new offer to Thailand

Darunavir looking promising as companion for agents in new HIV drug classes